H.R. 3093 · 118th Congress
Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 118th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
HoyleSponsor18 cosponsors · 18 D
D
Cohen
RD
D
DeLauro
LD
D
Doggett
RG
D
Grijalva
CG
D
García
PJ
D
Jayapal
MK
D
Kaptur
RK
D
Khanna
EN
D
Norton
CP
D
Pingree
MP
D
Pocan
JS
D
Schakowsky
MS
D
Stansbury
JT
D
Tokuda
GC
D
Casar
MT
D
Takano
SM
D
Magaziner
RT
D
Tlaib14 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 202 3
What it does: CRS summary · Introduced in House · May 5, 2023
Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023
This bill requires companies that receive federal funding for research (or a license of the rights to a patent or regulatory test data) for a biomedical product or service to agree to set reasonable prices for the resulting biomedical product or service.
The Department of Health and Human Services (HHS) must determine a reasonable price based on a formula that ensures the U.S. price for the product or service is not more than the median price for the product or service in Canada and six other reference countries with, based on specified criteria, large economies and high incomes.
Companies entering these agreements also must report to HHS certain financial information related to the biomedical product or service involved.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023
Latest action (May 12, 2023): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: May 5, 2023
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.